Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
- PMID: 17292768
- DOI: 10.1016/S0140-6736(07)60235-9
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
Abstract
Background: Resistance to antibiotics is a major public-health problem, and studies that link antibiotic use and resistance have shown an association but not a causal effect. We used the macrolides azithromycin and clarithromycin to investigate the direct effect of antibiotic exposure on resistance in the oral streptococcal flora of healthy volunteers.
Methods: Volunteers were treated with azithromycin (n=74), clarithromycin (74), or placebo (76) in a randomised, double-blind trial. Pharyngeal swabs were obtained before and after administration of study treatment through 180 days. The proportion of streptococci that were macrolide resistant was assessed and the molecular basis of any change in resistance investigated. Analyses were done on an intent-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00354952.
Findings: The number of dropouts (n=20) was much the same in all groups until day 42; dropouts increased substantially at day 180 (105). Both macrolides significantly increased the proportion of macrolide-resistant streptococci compared with the placebo at all points studied, peaking at day 8 in the clarithromycin group (mean increase 50.0%, 95% CI 41.7-58.2; p<0.0001) and at day 4 in the azithromycin group (53.4%, 43.4-63.5; p<0.0001). The proportion of macrolide-resistant streptococci was higher after azithromycin treatment than after clarithromycin use, with the largest difference between the two groups at day 28 (17.4% difference, 9.2-25.6; p<0.0001). Use of clarithromycin, but not of azithromycin, selected for the erm(B) gene, which confers high-level macrolide resistance.
Interpretation: This study shows that, notwithstanding the different outcomes of resistance selection, macrolide use is the single most important driver of the emergence of macrolide resistance in vivo. Physicians prescribing antibiotics should take into account the striking ecological side-effects of such antibiotics.
Comment in
-
Attention prescribers: be careful with antibiotics.Lancet. 2007 Feb 10;369(9560):442-3. doi: 10.1016/S0140-6736(07)60208-6. Lancet. 2007. PMID: 17292745 No abstract available.
Similar articles
-
Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study.Antimicrob Agents Chemother. 2004 Nov;48(11):4183-8. doi: 10.1128/AAC.48.11.4183-4188.2004. Antimicrob Agents Chemother. 2004. PMID: 15504839 Free PMC article. Clinical Trial.
-
Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers.Eur J Clin Microbiol Infect Dis. 2002 Jun;21(6):427-31. doi: 10.1007/s10096-002-0728-y. Epub 2002 Jun 11. Eur J Clin Microbiol Infect Dis. 2002. PMID: 12111597 Clinical Trial.
-
Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora.Int J Antimicrob Agents. 2005 Jan;25(1):68-74. doi: 10.1016/j.ijantimicag.2004.08.011. Int J Antimicrob Agents. 2005. PMID: 15620829
-
Clinical implications of macrolide resistance in community-acquired respiratory tract infections.Expert Rev Anti Infect Ther. 2006 Dec;4(6):973-80. doi: 10.1586/14787210.4.6.973. Expert Rev Anti Infect Ther. 2006. PMID: 17181414 Review.
-
The macrolides: erythromycin, clarithromycin, and azithromycin.Mayo Clin Proc. 1999 Jun;74(6):613-34. doi: 10.4065/74.6.613. Mayo Clin Proc. 1999. PMID: 10377939 Review.
Cited by
-
Resistome in a changing environment: Hotspots and vectors of spreading with a focus on the Russian-Ukrainian War.Heliyon. 2024 Jun 8;10(12):e32716. doi: 10.1016/j.heliyon.2024.e32716. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 39183836 Free PMC article. Review.
-
Gonococcal resistance can be viewed productively as part of a syndemic of antimicrobial resistance: an ecological analysis of 30 European countries.Antimicrob Resist Infect Control. 2020 Jun 30;9(1):97. doi: 10.1186/s13756-020-00764-z. Antimicrob Resist Infect Control. 2020. PMID: 32605597 Free PMC article.
-
Macrolide Treatment Failure due to Drug-Drug Interactions: Real-World Evidence to Evaluate a Pharmacological Hypothesis.Pharmaceutics. 2022 Mar 25;14(4):704. doi: 10.3390/pharmaceutics14040704. Pharmaceutics. 2022. PMID: 35456537 Free PMC article.
-
Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Clin Microbiol Rev. 2010 Jul;23(3):590-615. doi: 10.1128/CMR.00078-09. Clin Microbiol Rev. 2010. PMID: 20610825 Free PMC article. Review.
-
Targeting Epithelium Dysfunction and Impaired Nasal Biofilms to Treat Immunological, Functional, and Structural Abnormalities of Chronic Rhinosinusitis.Int J Mol Sci. 2023 Aug 3;24(15):12379. doi: 10.3390/ijms241512379. Int J Mol Sci. 2023. PMID: 37569753 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical